Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease
Data files
Aug 09, 2024 version files 1.72 GB
-
data_main_folder.zip
-
README.md
Abstract
Trachoma is a leading cause of infection-related blindness worldwide. This disease is caused by recurrent Chlamydia trachomatis (Ct) infections of the conjunctiva and develops in two phases: i) active (acute trachoma, characterized by follicular conjunctivitis), then long-term: ii) scarring (chronic trachoma, characterized by conjunctival fibrosis, corneal opacification, and eyelid malposition). Scarring trachoma is driven by the number and severity of reinfections. The immune system plays a pivotal role in trachoma including exacerbation of the disease. Hence the immune system may also be key to developing a trachoma vaccine. Therefore, we characterized clinical and local immune response kinetics in a non-human primate model of acute conjunctival Ct infection and disease. The conjunctiva of a non-human primate (NHP, Cynomolgus monkeys - Macaca fascicularis-) was inoculated with Ct (B/Tunis-864 strain, B serovar). Clinical ocular monitoring was performed using a standardized photographic grading system, and local immune responses were assessed using multi-parameter flow cytometry of conjunctival cells, tear fluid cytokines, immunoglobulins, and Ct quantification. Clinical findings were similar to those observed during acute trachoma in humans, with the development of typical follicular conjunctivitis from the 4th week post-exposure to the 11th week. Immunologic analysis indicated an early phase influx of T cells in the conjunctiva and elevated interleukins 4, 8, and 5, followed by a late phase monocytic influx accompanied by a decrease in other immune cells, and tear fluid cytokines returning to initial levels. Our NHP model accurately reproduces the clinical signs of acute trachoma, allowing for an accurate assessment of the local immune responses in infected eyes. A progressive immune response occurred for weeks after exposure to Ct, which subsided into a persistent innate immune response. An understanding of these local responses is the first step toward using the model to assess new vaccines and therapeutic strategies for disease prevention.
README: Multimodal mucosal and systemic immune characterization of a novel non-human primate trachoma model highlights the critical role of local immunity during acute phase disease
https://doi.org/10.5061/dryad.69p8cz982
This dataset contains results characterizing our model of trachoma (non-human primate). Those results comprise clinical scoring to assess the clinical signs, bacterial quantification to assess the conjunctival infection by Chlamydia trachomatis, as well as local and systemic immune assessment (conjunctival immune population with flow cytometry, immunoglobulin, and cytokines quantifications).
Description of the data and file structure
Results are organized by type of data, each data type in a different folder.
Clinical scoring is compiled in a single Excel file of clinical scoring results (on a scale of 0 to 8 for total scoring, 0 to 3 for inflammation score, and 0 to 5 for follicles score).
Bacterial loads of conjunctival Chlamydia trachomatis are compiled in a single Excel file with qPCR results expressed in equivalent copies of IFU (inclusion forming unit) per µL.
Flow cytometry results are put as FCS files raw from any analysis with a separate folder for each timepoint and a different folder for compensation files. Each animal is a different FCS file.
Cytokine quantifications are compiled in a single Excel file. Each cytokine is expressed in pg per µL.
Immunoglobulin quantifications are compiled in a single Excel file and expressed in titers.
For every Excel file, cells were left blank when the data wasn't available.
Sharing/Access information
These data are not accessible in any other way and are not derived from other sources.